For example, the PI3K inhibitor XL147 was reported to inhibit the PI3K pathway with a 40–80% reduction in the phosphorylation of AKT and 4EBP1 in tumours and unexpectedly inhibited the MEK/ERK pathway in a phase I trial [111]. This evidence concerns the gene PIK3CA and neoplasm.